Stock MDGL MADRIGAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Real-time Estimate Cboe BZX
Other stock markets
 01:19:08 2024-06-03 pm EDT 		5-day change 1st Jan Change
240.8 USD +1.98% Intraday chart for Madrigal Pharmaceuticals, Inc. +8.09% +4.31%
May. 19 Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
May. 19 Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
AQ
Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Pre Funded Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Performance Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Restricted Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Certain Options of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing
MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating
MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
MT
Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell
MT
Transcript : Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
Madrigal: Q1 Earnings Snapshot
AQ
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
AQ
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals
AQ
Madrigal Statement on the Passing of Dr. Stephen Harrison
AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. News Madrigal Pharmaceuticals, Inc.